• Peripheral blood mononuclear cells (PBMC) isolated using Lymphoprep.
• Subsequently, the monocyte fraction was enriched using plastic adherence
• The monocytes were cultured in six-well plates at a concentration of 107 cells per mL in short-term culture medium
• This medium consisted of RPMI-1640 supplemented with Glutamine, Penicillin, Streptomycin and autologous plasma
• The monocyte were differentiated into immature DCs by culture in the presence of recombinant human GM-CSF and recombinant human IL-4 for 7 days
• After 7 days, the immature DC were collected, maturation was induced with a cytokine mixture consisting of recombinant TNF-a and recombinant IL-1 and PGE2
DC vaccines were injected Intradermally (ID) in the upper arms, were given week 1 and 3, 2-weekly interval and 4-weekly interval.
• Only mild adverse events were observed in all the patients during the vaccination
• Grade II transient hematologic toxicity was seen in 2 patients
• Transient increase in focal neurologic signs in 6 patients. Headache in 9 patients, vomitus in 2 patients and flu-like symptoms in 3 patients
• Median progression-free survival (PFS) of all the patients was 3 months and median overall survival (OS) was 9.6 months• 1-year median OS was 37.4%, 2-year median OS was 14.8% and 3- year median OS was 11.1% • Age 35> had better median OS with 15.4 months and 7.5 months for patients older then 35 years old.
Adjuvant Dendritic cell-based Immunotherapy for patients with relapsed GBM is safe and can induce long-term survival.
Article Reference link: click here
Scientific article publishing date: 5/15/2008
Immucura identifier BSC21_334EN